Telmisartan Protects against Vascular Dysfunction with Peroxisome Proliferator-Activated Receptor-γ Activation in Hypertensive 5/6 Nephrectomized Rats

Pharmacology

Volumn 92, Issue 5-6, 2014, Pages 265-275

  Toba, Hiroe ^a   Wang, Jiahong ^a   Ohigashi, Makoto ^a   Kobara, Miyuki ^a   Nakata, Tetsuo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Aorta; Chronic kidney disease; Hypertension; Peroxisome proliferator activated receptor

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANGIOTENSIN 1 RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOSARTAN; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; ACETYLCHOLINE; CREATININE; NITROGEN; NITROPRUSSIDE SODIUM; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; HYPERPLASIA; HYPERTENSION; KIDNEY; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; VASCULAR DISEASE; VASODILATATION; ANIMAL TISSUE; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CELL INFILTRATION; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; ENDOTHELIUM; ENZYME ACTIVATION; GENE EXPRESSION; MEAN ARTERIAL PRESSURE; PROTEIN URINE LEVEL; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; VASCULAR RING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANILIDES; ANIMALS; AORTA; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DRUG PARTIAL AGONISM; ENDOTHELIUM, VASCULAR; HYPERTENSION; LOSARTAN; MALE; NITRIC OXIDE SYNTHASE TYPE III; PPAR GAMMA; RATS; RATS, WISTAR; VASODILATION;

EID: 84892951282     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000355482     Document Type: Article

References (52)

1. Meguid El Nahas A, Bello AK: Chronic kidney disease: The global challenge. Lancet 2005; 365: 331-340.
2. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266.
3. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119.
4. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996; 49: 1428-1434.
5. Agrawal B, Berger A, Wolf K, Luft FC: Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223-228.
6. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
7. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402-1407.
8. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-526.
9. Ritz E, McClellan WM: Overview: Increased cardiovascular risk in patients with minor renal dysfunction: An emerging issue with farreaching consequences. J Am Soc Nephrol 2004; 15: 513-516.
10. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
11. Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
12. Nishimoto-Hazuku A, Node K: Prevention of CVD in patients with CKD (in Japanese). Nihon Rinsho 2008; 66: 1741-1745.
13. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR- modulating activity. Hypertension 2004; 43: 993-1002.
14. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
15. Takai S, Jin D, Kimura M, Kirimura K, Sakonjo H, Tanaka K, Miyazaki M: Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferatoractivated receptor- agonistic property in rats. Hypertens Res 2007; 30: 1231-1237.
16. Toba H, Tojo C, Wang J, Noda K, Kobara M, Nakata T: Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor- in subtotal nephrectomized rat. Eur J Pharmacol 2012; 685: 91-98.
17. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: From orphan receptors to drug discovery. J Med Chem 2000; 43: 527- 550.
18. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull- Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41: 6640-6650.
19. Shobeiri N, Adams MA, Holden RM: Vascular calcification in animal models of CKD: A review. Am J Nephrol 2010; 31: 471-481.
20. Augustyniak RA, Picken MM, Leonard D, Zhou XJ, Zhang W, Victor RG: Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: Studies in sympathectomized rats. Clin Exp Pharmacol Physiol 2010; 37: 12-18.
21. Fujihara CK, Antunes GR, Mattar AL, Malheiros DM, Vieira JM Jr, Zatz R: Chronic inhibition of nuclear factor-B attenuates renal injury in the 5/6 renal ablation model. Am J Physiol Renal Physiol 2007; 292:F92-F99.
22. Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M: Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor- activation in diabetic mice. J Hypertens 2010; 28: 1730-1737.
23. Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J, Isobe M: Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR-. Lab Invest 2011; 91: 932-944.
24. Toyama K, Nakamura T, Kataoka K, Yasuda O, Fukuda M, Tokutomi Y, Dong YF, Ogawa H, Kim-Mitsuyama S: Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type diabetes, partially through peroxisome proliferator activated receptor-dependent activity. Biochem Biophys Res Commun 2011; 410: 508- 513.
25. Foulquier S, Dupuis F, Perrin-Sarrado C, Gate KM, Leroy P, Liminana P, Atkinson J, Capdeville-Atkinson C, Lartaud I: Differential effects of short-term treatment with two AT receptor blockers on diameter of pial arterioles in SHR. PLoS One 2012; 7: 5.
26. Khan AH, Imig JD: Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am J Hypertens 2011; 24: 816-821.
27. Morris ST, McMurray JJ, Rodger RS, Jardine AG: Impaired endothelium-dependent vasodilatation in uraemia. Nephrol Dial Transplant 2000; 15: 1194-1200.
28. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653- 1659.
29. Moncada S, Palmer RM, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109- 142.
30. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM: Peroxisome proliferator-activated receptor- ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor- dependent mechanisms. Arterioscler Thromb Vasc Biol 2005; 25: 1810-1816.
31. Gonon AT, Bulhak A, Labruto F, Sjoquist PO, Pernow J: Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor- ligand, in relation to nitric oxide. Basic Res Cardiol 2007; 102: 80-89.
32. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H: Cardioprotective mechanism of telmisartan via PPAR-eNOS pathway in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2008; 21: 576-581.
33. Blankenberg S, Barbaux S, Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
34. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
35. Michel JB, Thaunat O, Houard X, Meilhac O, Caligiuri G, Nicoletti A: Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol 2007; 27: 1259-1268.
36. Moos MP, John N, Grabner R, Nossmann S, Gunther B, Vollandt R, Funk CD, Kaiser B, Habenicht AJ: The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 2386-2391.
37. Moreno PR, Purushothaman KR, Zias E, Sanz J, Fuster V: Neovascularization in human atherosclerosis. Curr Mol Med 2006; 6: 457-477.
38. Seo HS, Lombardi DM, Polinsky P, Powell- Braxton L, Bunting S, Schwartz SM, Rosenfeld ME: Peripheral vascular stenosis in apolipoprotein E-deficient mice. Potential roles of lipid deposition, medial atrophy, and adventitial inflammation. Arterioscler Thromb Vasc Biol 1997; 17: 3593-3601.
39. Fukuda D, Enomoto S, Nagai R, Sata M: Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother 2009; 63: 754-761.
40. Jin D, Takai S, Li Z, Sakonjo H, Otsuki Y, Shibayama Y, Miyazaki M: Outside fibroblasts play a key role in the development of inner neointima after the implantation of polytetrafluoroethylene grafts. J Pharmacol Sci 2012; 119: 139-149.
41. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K: Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993; 92: 2814-2820.
42. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM: Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994; 74: 214-224.
43. Cicha I, Urschel K, Daniel WG, Garlichs CD: Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-. Clin Hemorheol Microcirc 2011; 48: 65-73.
44. Li AC, Glass CK: PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004; 45: 2161-2173.
45. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK: A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-. Nature 2005; 437: 759-763.
46. Tian Q, Miyazaki R, Ichiki T, Imayama I, Inanaga K, Ohtsubo H, Yano K, Takeda K, Sunagawa K: Inhibition of tumor necrosis factor-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator- activated receptor- with nuclear factor-B and CCAAT/enhancer-binding protein-. Hypertension 2009; 53: 798-804.
47. Oyama Y, Akuzawa N, Nagai R, Kurabayashi M: PPAR- ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. Circ Res 2002; 90: 348-355.
48. Gizard F, Bruemmer D: Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-: Therapeutic implications for cardiovascular diseases. PPAR Res 2008; 2008: 429123.
49. Ikejima H, Imanishi T, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T: Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator- activated receptor-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hypertens 2008; 26: 964-972.
50. Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Tager M, Bode-Boger SM: Effect of telmisartan on nitric oxide - asymmetrical dimethylarginine system: Role of angiotensin II type receptor- and peroxisome proliferator-activated receptor- signaling during endothelial aging. Hypertension 2008; 51: 696-703.
51. Bakris G, Burgess E, Weir M, Davidai G, Koval S: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74: 364-369.
52. Kusunoki H, Taniyama Y, Azuma J, Iekushi K, Sanada F, Otsu R, Iwabayashi M, Okayama K, Rakugi H, Morishita R: Telmisartan exerts renoprotective actions via peroxisome proliferator- activated receptor-/hepatocyte growth factor pathway independent of angiotensin II type receptor blockade. Hypertension 2012; 59: 308-316.